Bloomberg BusinessweekBloomberg Businessweek

New Hope for People Battling With Depression

View descriptionShare

Compass Pathways is a mental health care company developing new treatments for people who haven’t responded to existing medications and continue to struggle with their mental health. The company was the first to report successful Phase 3 clinical trial results for a psychedelic treatment, known as COMP360 psilocybin, for treatment-resistant depression (TRD) and is positioned to potentially be the first to receive regulatory approval and bring a psychedelic-based medicine to market.

Kabir Nath, the CEO of Compass Pathways, details his company's path building a scalable, safe, and accessible psychedelic care system and model. Kabir speaks with Carol Massar and Alexis Christoforous on Bloomberg Businessweek Daily.

  • Facebook
  • X (Twitter)
  • WhatsApp
  • Email
  • Download

In 1 playlist(s)

  1. Bloomberg Businessweek

    5,052 clip(s)

Bloomberg Businessweek

Carol Massar and Tim Stenovec bring you reporting from the magazine that helps global leaders stay a 
Social links
Follow podcast
Recent clips
Browse 5,053 clip(s)